Irrimax Corporation Continues Strategic Expansion in Targeted International Markets
Signs New Distribution Partners in Three Countries
LAWRENCEVILLE, Ga. – October 12, 2022 …
Read More
TEC Mailing Solutions’ New Service Addresses Direct-to-Consumer Fulfillment Challenges
Hurricane Ian’s Impact on Direct-to-Consumer Pharmaceutical Fulfillment Exacerbates an Already Vexing Challenge.
MADISON, Wis. – October 12, 2022 – (Newswire.com)
TEC Mailing Solutions, LLC, launches new service to improve the deliverability of life saving, direct-to-consumer pharmaceuticals to track the changes of new mover data.
Just like the waves of an ocean, the population continues to ebb and flow nationally at the rate of thousands of people per day. The migration has been steadily building in Fort Myers for the last decade and now the flow is retracting, as thousands of misplaced households are on the move in a small region.
No matter how or which way the population flows, it is creating new challenges for cadence-based shippers, those fulfilling subscriptions and more importantly life-saving prescriptions. Residents of Fort Myers who were receiving their medications through the mail will be unable to obtain vital packages.
The best data source to track new residences and address changes is the USPS National Change of Address database, which maintains move update information for the prior 48 months. Providers like TEC Mailing Solutions have unique features for the pharmaceutical industry that apply to anyone who has moved and filed a change of address with the postal service.
“We’ve been tracking live return data from our Pharmaceutical clients and effectively implementing safeguards to ensure our clients enjoy the best deliverability,” explains President Brian Euclide, President of TEC Mailing Solutions. “Returns due to change of address is a billion-dollar problem. This is a challenge we’re honored to solve.”
There will be lessons learned from IAN. Data will reveal the scale of devastation. Thankfully, there is new thinking and technology from private industry taking these challenges head-on. TEC Mailing’s Verify & Confirm™ product stops orders and packages from going to vacant or abandoned homes, buildings and people who have recently moved. Verify & Confirm™ also finds the current address of those who have filed a change of address. TEC Mailing ensures that each address is not only correct and complete but also current, in a first-of-its-kind implementation, specifically for direct-to-consumer pharmaceutical fulfillment.
About: TEC Mailing Solutions LLC is a Software as a Service (SaaS) provider of name, address hygiene, bulk mail and parcel sortation services for web-to-print, CRM, OEM, ERP, and variable digital printing solutions. TEC Mailing’s services are embedded functions in applications to improve workflow or standalone web portals: MailListCleaner®, MailPreparer™, MailPieceTracker™, ParcelPrep™, and Verify & Confirm are available direct or through a network of resell/referral partners and VARs. Privately held, the corporate office is in Sun Prairie, Wisconsin. Find more information at http://www.tecmailing.com or call 866-379-9437.
Contact Information:
Scott Eganhouse
VP
16082175515
Press Release Service
by
Newswire.com
Original Source:
TEC Mailing Solutions’ New Service Addresses Direct-to-Consumer Fulfillment Challenges
Apgar & Associates Achieves HITRUST® Readiness Licensee Designation
Designee builds on commitment to furthering excellence in the healthcare sector’s information security and privacy programs
Apgar & Associates logo
infosec and privacy consultants Apgar & Associates logo, HITRUST designee
PORTLAND, Ore. – October 12, 2022 – (Newswire.com)
Apgar & Associates, LLC today announced that it is designated as a HITRUST Readiness Licensee. With this achievement, Apgar & Associates is approved by HITRUST to perform consulting and readiness work for organizations looking to adopt the HITRUST CSF or prepare for their first assessment. For over a decade, the consultancy has provided information security and privacy services that encompass strategic planning for risk management and compliance programs, as well as consulting on security incidence response, risk analysis, and policy and procedures.
HITRUST Readiness Licensees help uphold information security and privacy standards for various industries of varying size and complexity by assisting clients with the adoption of the HITRUST CSF framework, implementation, and remediation efforts following adoption, and facilitated self-assessments.
“We’re very pleased to receive the HITRUST Readiness designation. It feels like a natural progression in our firm’s commitment to furthering excellence in the healthcare sector’s information security and privacy programs,” stated Julia Huddleston, CIPP/US, CIPM, CCSFP, and Principal Consultant at Apgar & Associates, LLC. “We look forward to helping guide healthcare providers and their business associates through the what and how of readying for the HITRUST assessment.”
“Readiness Licensees meet the criteria to become trusted and independent resources for clients needing to improve their security posture,” said Matthew Datel, Director, Education & Strategic Initiatives at HITRUST. “Readiness Licensees are helpful in providing qualified third-party reviews for clients preparing for or seeking HITRUST CSF Certification.”
About Apgar & Associates
The consultancy’s information security and privacy services encompass strategic planning for risk management and compliance programs, as well as consulting on security incidence response, risk analysis, and policy and procedures.
The team also helps organizations decide which of the various industry certifications aligns best with the business’ privacy and information security strategy. For more information about Apgar & Associates’ consulting services, such as HITRUST Readiness, please contact the company at 503-384-2538 or visit its website at https://apgarandassoc.com/.
Contact Information:
Nora Haile
Marketing Consultant
520-425-6498
Press Release Service
by
Newswire.com
Original Source:
Apgar & Associates Achieves HITRUST® Readiness Licensee Designation
Group Dentistry Now and Seattle Study Club Enter Into a Strategic Agreement to Bring Continuing Education to DSOs and Emerging Dental Groups
The agreement brings together two industry leaders, leveraging complementary strengths to enhance support of doctors in building successful dental practices. This new education platform is called Group Dentistry Instit…
JAMES CHARLES MAKEUP LINE DROPS SPRING 2023 BUT IS IT TO LATE?
JAMES CHARLES THE DOWNFALL BEGAIN WITH HIMSELF NOT JEFFREE STAR OR TATI WESTBROOK, OR SHANE DAWSON
BUY MY PALETTE HERE USE CODE RICH LUX
#JAMESCHARLES #jeffreestar #shanedawson
Troomy Nootropics Launches Line of All-Natural, Functional Mushroom Gummies
New line of mushroom-powered gummies targets creating quick natural health benefits in the daily routine.
Troomy Mushroom Gummies
…
Tom Holland Reacts To Zendaya And Timothee Chalamet’s Relationship
Tom Holland Reacts To Zendaya And Timothee Chalamet’s Relationship Wait! Did we hear fans calling for a throuple between Timothée Chalamet, Zendaya, and Tom Holland? Okay, what in the love triangle is brewing? And what do Tim, Tom, and Zendaya think about the entire situation? Given! Thousands of fans love to see Tom and Zendaya […]
Tom Holland Reacts To Zendaya And Timothee Chalamet’s Relationship
Tom Holland Reacts To Zendaya And Timothee Chalamet’s Relationship Wait! Did we hear fans calling for a throuple between Timothée Chalamet, Zendaya, and Tom Holland? Okay, what in the love triangle is brewing? And what do Tim, Tom, and Zendaya think about the entire situation? Given! Thousands of fans love to see Tom and Zendaya […]
The Animal Eye Institute Announces a New Location in Charleston, South Carolina
Dr. Korb Dr. Korb with her dogs, Charlie and Tucker
CHARLESTON, S.C. – October 11, 2022 – (Newswire.com)
…
Ambit Inc. to Present Novel Projection Methodology for Rare Developmental and Epileptic Encephalopathies (DEEs) at the 2022 Child Neurology Society Annual Meeting
Ambit to showcase its prevalence projection approach, co-developed with Praxis, for rare developmental and epileptic encephalopathies (DEEs) as a Platform Presentation at this year’s annual Child Neurology Society meeting
CINCINNATI – October 11, 2022 – (Newswire.com)
Ambit®, a data and technology-enabled biopharma services company, today announced that leadership will debut Ambit’s data-driven methodology for projecting prevalence and diagnosis rates for difficult-to-quantify DEEs at the 51st Annual Child Neurology Society Meeting on Oct. 13, 2022. Ambit’s analytics team has developed this methodology in collaboration with Praxis Precision Medicines, Inc. (NASDAQ: PRAX) and the UCSF Weill Institute for Neurosciences and Benioff Children’s Hospitals.
For many rare DEEs, reliable prevalence estimates are not available. With a robust and growing pipeline of precision medicine therapies in rare epilepsy and neurodevelopmental disorders, estimating the prevalence of these conditions with a data-driven methodology can be highly valuable to drug developers, medical device companies and other healthcare decision-makers.
“Ambit’s expertise in a data-driven approach to prevalence projections for rare neurological conditions has allowed Praxis to characterize DEE populations with a high degree of confidence,” said Marcio Souza, president and chief executive officer of Praxis. “As we seek to bring first-in-class, potentially disease-modifying therapies to DEE patients in need, our collaboration with Ambit has been invaluable in increasing our understanding of these patient groups.”
Despite the availability of sponsored genetic testing and increased awareness of the benefit of genetic testing, over 50% of patients with rare DEEs remain undiagnosed. Sizing these patient populations and diagnosis rates underscores the importance of earlier genetic testing for unexplained seizure disorders and rare DEEs. “Even today, the path to accurate diagnosis and appropriate care for rare genetic epilepsies can be long and full of challenges,” said Adam Numis, M.D., of the UCSF Benioff Children’s Hospital. “Ambit’s methodology underscores the need for more treatment options to improve outcomes and quality of life for the rare DEE population.”
Ambit chief executive officer, Robert Sederman, will present this methodology on Oct. 13 as part of the Platform II Presentation Session (PL2-1) at the 2022 Annual Child Neurology Society Meeting. Presentations will run from 7-9 a.m. ET in the Junior Ballroom CD at the Duke Energy Center. Ambit will be presenting from 7-7:15 a.m. The associated abstract will be published in a supplement to the October issue of Annals of Neurology.
“We are excited to partner with Praxis and UCSF to showcase Ambit’s DEE projection methodology at this year’s meeting and, ultimately, see the impact of this collaboration on greater access to accurate diagnosis and treatment for patients with rare DEEs in the future,” said Sederman.
About Ambit Inc.
Ambit Inc.® is a data and technology-enabled biopharma and healthcare services company with a focus on rare and specialty disease. Ambit’s patient identification services drive patient activation and earlier diagnosis for patients that may be suffering from rare diseases. Ambit’s analytics and professional services support rare and specialty biopharma across the clinical development and commercialization of potentially life-changing therapies. To learn more about Ambit’s DEE Projection approach and other capabilities, please reach out to inquiries@ambitinc.com.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying insights from genetic epilepsies to both rare and more prevalent neurological disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio with multiple programs, including product candidates across movement disorders, epilepsy and psychiatric disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.
Contact Information:
Alexis Burbank
Marketing, Ambit Inc.
Press Release Service
by
Newswire.com